Nicotine Wilko (Nicotine Resinate)

Nicotine Resinate, the active ingredient in Nicotine Wilko, is a nicotinic agonist presented as an oral tablet for oral use. It is intended to help adult smokers manage nicotine dependence and reduce withdrawal symptoms during cessation attempts.

GNH USA supplies Nicotine Wilko as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Nicotine Wilko is a nicotinic agonist used within the smoking cessation pathway to aid adults who wish to quit tobacco use.

Smoking cessation: assists adult smokers in quitting by reducing cravings and withdrawal symptoms. Nicotine dependence: alleviates withdrawal symptoms during cessation attempts. Tobacco use disorder: supports reduction of tobacco consumption when combined with behavioral counseling.

Nicotine Wilko may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea or upset stomach. - Headache. - Dizziness or light‑headedness. - Insomnia or sleep disturbances. - Mild oral irritation. - Increased salivation.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty. - Persistent cardiovascular symptoms such as palpitations or hypertension. - Unexplained chest pain. - Severe gastrointestinal upset leading to vomiting.

When using Nicotine Wilko, consider the following safety measures.

Avoid use in patients with uncontrolled hypertension: monitor blood pressure regularly. Do not combine with other nicotine replacement products without medical guidance: risk of nicotine overdose. Use caution in individuals with cardiovascular disease: assess risk‑benefit ratio. Pregnancy and breastfeeding: consult a healthcare professional before use. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nicotine Wilko can interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may amplify nicotine’s cardiovascular effects. - Certain antihypertensive agents: nicotine can counteract blood‑pressure‑lowering actions. - CYP2A6 inhibitors: may increase nicotine plasma concentrations.

Moderate Interactions (Monitor Closely): - Caffeine‑containing products: may increase stimulant effects. - Antidepressants (SSRIs, SNRIs): monitor for heightened anxiety or insomnia. - Oral contraceptives: nicotine may reduce contraceptive efficacy; advise alternative methods.